Table 3.
Univariate analysis and multivariate analysis on OS and PFS in 142 EGFR and ALK wild type stage IV NSCLC with MPE.
| Characteristics | OS | PFS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| P | HR | 95% CI | P | P-value | HR | 95% CI | P | |
| Age (≤70/>70) | 0.267 | 0.915 | 0.559–1.496 | 0.722 | 0.209 | 1.257 | 0.819–1.927 | 0.295 |
| Male | 0.005 | 1.864 | 0.965–3.598 | 0.064 | 0.091 | 1.323 | 0.865–2.022 | 0.197 |
| Smoking status (ever/never) | 0.032 | 1.020 | 0.544–1.914 | 0.951 | 0.078 | |||
| Histology (Adenocarcinoma/Squamous cell) | 0.068 | 0.201 | ||||||
| ECOG (0–1/≥2) | 0.007 | 2.551 | 1.013–6.422 | 0.047 | 0.021 | 1.805 | 0.782–4.167 | 0.166 |
| T stage (1–2/3–4) | 0.436 | 0.832 | ||||||
| N stage (0–2/3) | 0.719 | 0.368 | ||||||
| M stage (M1a/M1b) | 0.126 | 0.462 | ||||||
| Treatment (1st line) (Conventional chemotherapy/Supportive care only) | <0.001 | 12.52 | 4.56–34.40 | <0.001 | — | |||
| Hemoglobin, g/dL (<12/≥12) | <0.001 | 2.035 | 1.046–3.959 | 0.036 | 0.002 | 1.668 | 0.906–3.071 | 0.096 |
| Platelet, per uL (<300,000/≥300,000) | 0.197 | 0.035 | 1.504 | 0.987–2.292 | 0.057 | |||
| Albumin, g/dL (<3.1/≥3.1) | <0.001 | 1.389 | 0.744–2.591 | 0.302 | 0.159 | |||
| CRP, mg/dL (<2.68/≥2.68) | <0.001 | 2.319 | 1.329–4.047 | 0.003 | 0.049 | 1.523 | 1.005–2.310 | 0.048 |
| Platelet/ Lymphocyte (<181.24/≥181.24) | 0.003 | 2.595 | 1.607–4.192 | <0.001 | 0.053 | |||
BMI: body mass index; CI: confidence interval; CRP: c-reactive protein; ECOG: Eastern Cooperative Oncology Group; HR: hazard ratio; LDH: lactate dehydrogenase; OS: overall survival; PFS: progression free survival.